These activated DCs, in turn, cross‐present tumor‐derived antigens to naïve or circulating CD8+ T cells, leading to the expansion of new cytotoxic T cell clones targeting both the original and neoantigens expressed by the tumor [69]. Here, CD8A is linked to neoplasm.